Research Projects & Grants

College/University

  • Millennium 03-1218/34102-033 MUSC CTO #100822: VELCADE® (bortezomib) for injection therapy for early relapsed prostate cancer, Role: Investigator, Medical University of South Carolina, (09/2009 - 09/2010) Status: Completed

Federal

  • End of life treatment decisions, Role: PI, Veterans Administration, (09/1997) Status: Completed

For Profit Organization

  • SWOG N0147. A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer, Role: Investigator, Southwest Oncology Group, (05/2014 - 05/2015) Status: Completed
  • Novartis - CSOM230C2303: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs. octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues, Role: Investigator, Novartis Pharmaceuticals Corporation, (06/2013 - 06/2014) Status: Completed
  • SWOG - S0941: Phase II study of sorafenib (NSC-724772) and erlotinib (NSC-718781) in patients with advanced gallbladder carcinoma or cholangiocarcinoma, Role: Investigator, Southwest Oncology Group, (03/2013 - 03/2014) Status: Completed
  • Wyeth research division of Wyeth Pharmaceuticals Inc. - 3129K7-2001-WW: A phase II study of inotuzumab ozogamicin (CMC-544) in subjects with indolent non-Hodgkin's lymphoma (NHL) that is refractory to or has relapsed after rituximab and chemotherapy or radioimmunotherapy, Role: Investigator, Wyeth Pharmaceuticals, Inc., (02/2013 - 02/2014) Status: Completed
  • Bristol-Myers Squibb - CA 184-043: A randomized, double-blind, phase III trial comparing Ipilimumab vs placebo following radiotherapy in subjects with Castration Resistant Prostate Cancer (CRPC) that have received prior treatment with Docetaxel, Role: Investigator, Bristol-Myers Squibb Company, (12/2012 - 12/2013) Status: Completed
  • Novartis - Protocol CRAD001J2101: A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer, Role: Investigator, Novartis Pharmaceuticals Corporation, (11/2012 - 11/2013) Status: Completed
  • BMS - CA182-034: A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to sorafenib: the BRISK PS study, Role: Investigator, Bristol-Myers Squibb Company, (10/2011 - 10/2012) Status: Completed
  • GlaxoSmithKline (GSK)-LPT109747 - An exploratory, phase II trial to determine the association of lapatinib induced fluoropyrimidine gene changes with efficacy parameters of lapatinib and capecitabine in first line gastric cancer, Role: Investigator, GlaxoSmithKline, (05/2011 - 05/2012) Status: Completed
  • Genmab-GEN205 - An open label single arm trial investigating zalutumumab, a human monoclonal anti-EGF receptor antibody, in combination with palliative care in patients with non-curable squamous cell carcinoma of the head and neck who have failed standard platinum-based chemotherapy, Role: Investigator, GENMAB, (05/2011 - 05/2012) Status: Completed
  • Oncotherapeutics - DVD-R-2009: A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide (DVD-R) for patients with relapsed/refractory multiple myeloma, Role: Investigator, Oncotherapeutics, (04/2011 - 04/2012) Status: Completed
  • OSI-774-302: A multi-center, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors (RADIANT), Role: Investigator, OSI Pharmaceuticals, Inc., (02/2011 - 02/2012) Status: Completed
  • Sanofi-Aventis-EFC 10261: A multi-center, randomized, double-blind study comparing aflibercept versus placebo in patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC), Role: Investigator, Sanofi-Aventis U.S., Inc., (01/2011 - 01/2012) Status: Completed
  • Oncotherapeutics - X05272/DOXILMMY2010: A phase II study of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) for patients with newly diagnosed Multiple Myeloma (MM), Role: Investigator, Oncotherapeutics, (10/2010 - 10/2011) Status: Completed
  • Millennium Pharmaceuticals, Inc. protocol C05012 - A two-arm, non-randomized, multicenter, phase 2 study of Velcade® (bortezomib) in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in subjects with relapsed follicular lymphoma, Role: Investigator, Millennium Pharmaceuticals, Inc., (08/2010 - 08/2011) Status: Completed
  • Aptium 05LUN01 - A phase I/II clinical trial of bortezomib (velcade) + pemetrexed (alimta) in previously treated patients with advanced non-small cell lung cancer, Role: Investigator, Aptium Oncology Research Network, (06/2010 - 06/2011) Status: Completed
  • Gloucester Pharmaceuticals, Inc. - GPI-08-0006: A phase II trial of romidepsin and bortezomib for multiple myeloma patients with relapsed or refractory disease, Role: Investigator, Gloucester Pharmaceuticals, Inc., (02/2010 - 02/2011) Status: Completed
  • Novartis - CASA404A2301: A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non small-cell lung cancer (NSCLC), Role: Investigator, Novartis Pharmaceuticals Corporation, (01/2010 - 01/2011) Status: Completed

Internal

  • Treatment decisions for patients at the end of life: how would medical students apply advance directives in difficult cases?, Role: PI, LLU Dept. of Medicine, (08/2000) Status: Completed

Non-Profit Organization

  • National Surgical adjuvant breast and bowel project (NSABP) R-04 a clinical trial comparing preoperative radiation therapy and capecitabine with or with out oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (05/2014 - 05/2015) Status: Completed